We’ve developed 12 treatments for six deadly diseases since 2003
Delivering better treatments for neglected patients
DNDi’s objective is to deliver 25 new treatments for neglected patients by 2028.
Since 2003, DNDi has worked with its worldwide network of partners to:
- develop two new chemical entities: fexinidazole, the first all-oral treatment for sleeping sickness, and ravidasvir, a simple-to-use and affordable treatment for hepatitis C
- develop 10 new treatments from existing molecules and recombining drugs to bring better treatments to patients for malaria, Chagas disease, leishmaniasis, HIV-visceral leishmaniasis co-infection, and paediatric HIV
- initiate GARDP, a not-for-profit research and development organization developing and delivering new or improved antibiotic treatments
Help neglected patients
To date, we have delivered twelve new treatments, saving millions of lives.
Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there.